Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Science translational medicine·2026
Same author

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Thrombosis research·2026
Same author

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

British journal of haematology·2026
Same author

Correction: Colarusso et al. Role of the AIM2 Inflammasome in Cancer: Potential Therapeutic Strategies. <i>Biomedicines</i> 2025, <i>13</i>, 395.

Biomedicines·2025
Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025
Same author

Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.

BMC bioinformatics·2025

Related Experiment Video

Updated: May 21, 2026

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry
07:29

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Published on: October 6, 2023

Microparticles in tumor progression.

Anna Falanga1, Carmen Julia Tartari, Marina Marchetti

  • 1Division of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy. annafalanga@yahoo.com

Thrombosis Research
|June 12, 2012
PubMed
Summary

Microparticles (MPs), released from blood cells, indicate cell death and disease. Elevated MPs, particularly from platelets, are linked to cancer and clotting risks, suggesting diagnostic potential.

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Related Experiment Videos

Last Updated: May 21, 2026

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry
07:29

Tracking miRNA Release into Extracellular Vesicles using Flow Cytometry

Published on: October 6, 2023

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
09:26

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells

Published on: February 20, 2015

Area of Science:

  • Hematology
  • Oncology
  • Biochemistry

Background:

  • Microparticles (MPs) are cell membrane fragments released during cell activation or apoptosis.
  • Their plasma levels reflect cellular dynamics and can indicate disease states.
  • Phosphatidylserine (PS) expression on MPs facilitates blood coagulation, especially when coupled with Tissue Factor.

Purpose of the Study:

  • To review the role of MPs in various clinical conditions, particularly malignancies.
  • To explore the association between elevated MPs and thrombotic risk.
  • To discuss the potential of MPs as diagnostic and prognostic markers.

Main Methods:

  • Literature review of studies investigating MP production and function.
  • Analysis of MP levels in patients with different clinical conditions, including malignancies.
  • Examination of the pro-angiogenic and pro-coagulant properties of MPs.

Main Results:

  • Increased MP levels are observed in numerous clinical conditions, correlating with heightened thrombotic risk.
  • Elevated MPs are particularly noted in solid and hematological malignancies, such as myeloproliferative neoplasms.
  • Platelet-derived MPs are implicated in tumor progression due to their pro-angiogenic factor content.

Conclusions:

  • MPs are significant biomarkers associated with increased thrombotic risk and cancer progression.
  • Further research is needed to establish the utility of MPs as diagnostic and prognostic tools.
  • Pharmacological inhibition of MP production presents a future therapeutic avenue.